Clinical trials: sponsored by Georgetown University
Exercise, Health Behavior
Physical Activity Smartphone App for African American Men (FitBros) Ph II
Low physical activity levels contribute to African American men experiencing health disparities across a number of chronic diseases.
- Conditions
- Exercise, Health Behavior, Technology
- Trial name
- NCT05621044
- Testing
- FitBrothers smartphone active app, Nike Training Club
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Immunosuppression Management, Biomarkers / Blood
PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)
This is an observational, prospective, multi-center trial designed to evaluate clinical outcomes in kidney transplant recipients undergoing TruGraf and TRAC monitoring. Approximately 15 U.S. sites
- Conditions
- Immunosuppression Management, Biomarkers / Blood, Subclinical Rejection, Biopsy
- Trial name
- PIONEER (NCT07231328)
- Testing
- There is no required Intervention for this Protocol. Based on Results for TruGraf/TRAC/TRAC ID Investigators may use the results in managing subjects Immunosuppression or rule out rejection.
- Volunteers
- 600 people
- Sponsor
- Transplant Genomics, Inc.
Migraine
Real-world Data Analysis of REN Treatment in Migraine Patients
Data analysis concerning four sets of metrics: A. Per-treatment patterns of REN use as a standalone treatment vs. in combination with medications. B.
- Trial name
- NCT04992897
- Testing
- Remote Electrical Neuromodulation (REN)
- Where
- 2 sites in United States, Israel
- Volunteers
- 12,151 people
- Sponsor
- Theranica
Chronic Pain, Low Back Pain
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)
The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain [CBOT-Pain (or CBOT-P)]…
- Trial name
- CBOT-P-2 (NCT06671132)
- Testing
- Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Evon Medics LLC
Chronic Pain, Low Back Pain
Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain
The overarching goal of this study phase, Phase I component is to configure Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) into Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment…
- Trial name
- CBOT-Pain (NCT06218407)
- Testing
- Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm, Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Evon Medics LLC
Chronic Aphasia
Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study
This Phase II study aims to ascertain the effectiveness of HD-tDCS for adjunctive treatment of anomia in chronic aphasia post stroke.
- Trial name
- NCT02540109
- Testing
- HD-tDCS (Soterix Medical, Active)
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Soterix Medical
Exercise, Health Behavior
Physical Activity Smartphone App for African American Men (FitBros) Phase I
Low physical activity levels contribute to African American men experiencing health disparities across a number of chronic diseases.
- Conditions
- Exercise, Health Behavior, Technology
- Trial name
- FitBros (NCT05509712)
- Testing
- Focus Groups to Refine MobileMen App Content, Beta testing of MobileMen App Prototype
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Prematurity, Premature Birth
Vibroacoustic Study of Lung Development in Newborn Infants
Investigators hypothesize that premature newborns with poor cardiopulmonary performance have higher morbidities and poorer physical and cognitive developmental outcomes.
- Conditions
- Prematurity, Premature Birth, Premature Lungs, Prematurity; Extreme
- Trial name
- NCT05827250
- Testing
- imPulse Tor
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Level 42 AI, Inc.
Non-Small Cell Lung Cancer
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had…
- Trial name
- NCT02706626
- Testing
- brigatinib
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Criterium, Inc.
Pancreas Cancer, Hepatobiliary Cancer
NCI SBIR Contract for Patient Navigation Tool Prototype Development
GMG ArcData will create a mobile-based application to improve communications and data exchange among patients and navigators involved in new pancreas surgery oncology episodes of care.
- Conditions
- Pancreas Cancer, Hepatobiliary Cancer, Patient Engagement
- Trial name
- NCT04892927
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GMG Arcdata LLC
Complex Lower Extremity Soft Tissue Reconstruction
Retrospective Study Evaluating Outcomes for Integra® Skin Sheet Products in Lower Extremity Complex Wounds
This is a retrospective, multi-center study evaluating the outcomes of using Integra® skin sheet bilayer or single layer products for complex soft tissue reconstruction of lower extremity diabetic wounds compared to other…
- Trial name
- NCT01947387
- Where
- 4 sites in United States
- Volunteers
- 320 people
- Sponsor
- Integra LifeSciences Corporation
Identify Characteristics of Colonoscopists During Endoscopy
Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy
The purpose of this study is to evaluate a handheld Colonoscopy Force Monitor(CFM™), a push-pull force and torque measuring device, that grips the shaft of the colonoscope and wirelessly transmits and records all the forces…
- Trial name
- NCT00797914
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Artann Laboratories
Compare Performance of Colonoscopists
Characterize Differences in Force Patterns Used by Different Endoscopists and Trainee Endoscopists
The study is to evaluate how doctors in training are different from very experienced doctors when using force to perform colonoscopy with a device that monitors the amount of force applied to the colonoscope during colonoscopy.
- Trial name
- NCT01029899
- Where
- 2 sites in United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Artann Laboratories
Outpatient Colonoscopy for Colorectal Cancer Screening or for Symptoms Suggestive of Colonic Diseases
Effect of Anesthesia on Force Application During Colonoscopy
The aim of the study is to determine if more force is used during colonoscopy when patients receive monitored anesthesia with propofol versus conscious sedation.
- Trial name
- CFM (NCT02101099)
- Testing
- Colonoscopy Force Monitor
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- Artann Laboratories
Neoplasms
Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
LErafAON is a liposome encapsulated c-raf antisense oligonucleotide. Raf-1 is a protein produced by human cells, both normal and cancerous, which may help protect tumor cells from radiation.
- Trial name
- NCT00024648
- Testing
- LErafAON
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- INSYS Therapeutics Inc
Neoplasms
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors
LErafAON is a liposome encapsulated c-raf antisense oligonucleotide. Raf-1 is a protein produced by human cells, both normal and cancerous, which may help protect tumor cells from radiation.
- Trial name
- NCT00024661
- Testing
- LErafAON
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- INSYS Therapeutics Inc